Enhanced TLR4 endothelial cell immunohistochemical expression in symptomatic carotid atherosclerotic plaques

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 1, 2010, Pages 1-10

  Katsargyris, Athanasios ^a   Theocharis, Stamatios E ^b   Tsiodras, Sotirios ^b   Giaginis, Konstantinos ^b   Bastounis, Elias ^a   Klonaris, Chris ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Cerebrovascular symptomatology; Endothelial cells immunohistochemistry; Toll like receptor 4

Indexed keywords

TOLL LIKE RECEPTOR 4;

AGED; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; VASCULAR ENDOTHELIUM;

AGED; AMAUROSIS FUGAX; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; ENDOTHELIAL CELLS; FEMALE; GRAFT OCCLUSION, VASCULAR; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; ISCHEMIC ATTACK, TRANSIENT; MALE; STROKE; THROMBOSIS; TOLL-LIKE RECEPTOR 4;

EID: 72549100982     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903401294     Document Type: Article

References (48)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126
2. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-1890
3. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005;26:1700-1704
4. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004;34:328-334
5. Tobias P, Curtiss LK. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res 2005;46:404-411
6. Curtiss LK, Tobias PS. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007;8:1230-1238
7. Hommels MJ, Kroon AA, Netea MG, et al. The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis. Neth J Med 2007;65:203-207
8. Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 2007;11:88-95
9. Liu X, Ukai T, Yumoto H, et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008;196:146-154
10. Katsargyris A, Klonaris C, Bastounis E, Theocharis S. Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease? Expert Opin Ther Targets 2008;12:1329-1346
11. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-1161
12. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-3108
13. Liapis CD, Bell PR, Mikhailidis D, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009;37:1-19
14. Howard G, Prineas R, Moy C, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke 2006;37:1171-1178 (Pubitemid 43731857)
15. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275
16. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191
17. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-192
18. Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23:e61-4
19. Vainas T, Stassen FR, Bruggeman CA, et al. Synergistic effect of Toll-like receptor 4 and CD14 polymorphisms on the total atherosclerosis burden in patients with peripheral arterial disease. J Vasc Surg 2006;44:326-332
20. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004;101:10679-10684
21. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10:416-421
22. Shiraki R, Inoue N, Kobayashi S, et al. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Life Sci 2006;80:59-66
23. Methe H, Kim JO, Kofler S, et al. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005;111:2654-2661
24. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-20
25. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143
26. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-397
27. Spagnoli LG, Mauriello A, Sangiorgi G, et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004;292:1845-1852
28. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 2007;48:1800-1815
29. Labrum R, Bevan S, Sitzer M, et al. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007;38:1179-1184 (Pubitemid 351664263)
30. Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, et al. NF-kB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 2004;35:458-463
31. Wilson SH, Best PJ, Edwards WD, et al. Nuclear factor-kB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 2002;160:147-153
32. Tureyen K, Vemuganti R, Salamat MS, Dempsey RJ. Increased angiogenesis and angiogenic gene expression in carotid artery plaques from symptomatic stroke patients. Neurosurgery 2006;58:971-977; discussion 971-977
33. McCarthy MJ, Loftus IM, Thompson MM, et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999;30:261-268
34. Mofidi R, Crotty TB, McCarthy P, et al. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001;88:945-950
35. Giannoni MF, Vicenzini E, Citone M, et al. Contrast carotid ultrasound for the detection of unstable plaques with neoangiogenesis: a pilot study. Eur J Vasc Endovasc Surg 2009;37:722-727
36. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005;96:15-26
37. Pollet I, Opina CJ, Zimmerman C, et al. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kB and c-Jun N-terminal kinase. Blood 2003;102:1740-1742
38. Pinhal-Enfield G, Ramanathan M, Hasko G, et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A2A receptors. Am J Pathol 2003;163:711-721
39. Erickson B, Sperber K, Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev 2008;16:273-279
40. Wang L, Li D, Yang K, et al. Toll-like receptor-4 and mitogen-activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome. Immunology 2008;125:122-130
41. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-43
42. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005;36:1796-1800
43. Hollestelle SC, De Vries MR, Van Keulen JK, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 2004;109:393-398
44. Hamann L, Gomma A, Schroder NW, et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med 2005;83:478-485
45. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 2006;113:2320-2328
46. Peeters W, Hellings WE, de Kleijn DP, et al. Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization. Arterioscler Thromb Vasc Biol 2009;29:128-133
47. Carr S, Farb A, Pearce WH, et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996;23:755-65; discussion 765-1756
48. Mauriello A, Sangiorgi GM, Virmani R, et al. A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis 2009; published online 3 August 2009, doi:10.1016/j. atherosclerosis.2009.07.048